MODERNA to cut 10% labor amid COVID vaccine sales

Modern On Thursday stated that it plans to cut approximately 10% of its global labor by the end of the year Continue to decrease And the company is uncertain about the vaccine market.

In recovery For employees, Moderna CEO Stefan Bansel said the company was waiting for less than 5,000 workers by the end of the year. As of 2024 Annual Report.

Moderna’s shares decreased by more than 20%this year. In May, the company reported the sale of the vaccine in the first quarter that missed Wall Street estimates. Moderna is also nugging Political obstacles According to the Secretary of Health and Human Services Robert F. Kennedy -Jr.

Also in May, Moderna stated that by 2027 would reduce annual operating costs by 1.5 billion Previously announced.

Moderna will provide another update of its business if it places quarterly results on Friday morning.

In memory. Bancel said Moderna has made significant progress towards reducing research and developments, especially since the test products are completed, the suppliers are talking and reducing production costs.

“Every effort was made to avoid impact on work,” he said. “But today, the reshuffle of our operating structure and the coordination of our structure on the reality of our business is important to remain focused and financially disciplined, continuing to invest in our science on the way to 2027.”

He said that “the future Moderna is bright”, noting that he has three approved products and potential before eight in the next three years. In May Management and Medicines approved The product of the third ever Moderna history, which broke out the next generation.

But Bansel said that “this decision was not made slightly.”

“It affects teammates and friends who have devoted themselves to our mission and helped build Moderna,” he said. “I want to express it on behalf of the entire executive committee and on behalf of the patients you served, we have deeply thanked for everything you have made.”